Moreover, single nucleotide polymorphisms (SNPs) in SLC28A1 are associated with altered bioavailability of the nucleoside analog drugs used to treat allograft rejection and hepatic toxicity when these drugs are used to treat non-small cell lung cancer (NSCLC)28,29. Here, SLC28A1 is linked to non-small cell lung carcinoma.